Key facts
- This page summarizes Tacey Viegas's Form 3 filing for AgeX Therapeutics, Inc. (SER).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 Apr 2024, 20:08.
Tacey Viegas - 26 Mar 2024 Form 3 Insider Report for AgeX Therapeutics, Inc. (SER)
- Reporting relationship
- COO and Secretary
- Issuer ticker
- SER
- Reported as of
- 26 Mar 2024
- Net transaction value
- $0
- Reporting owner signature
- /s/ Tacey Viegas
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Tacey Viegas filed Form 3 for AgeX Therapeutics, Inc. (SER) on 03 Apr 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SER
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 58,610
- Date
- 26 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SER
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 26 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 203,563
- Exercise price
- $0.0600
- Footnotes
- F1, F2
SER
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 26 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 138,326
- Exercise price
- $0.0600
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares of capital stock of the corporation then known as Serina Therapeutics, Inc. ("Serina AL") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of August 29, 2023, by and among the Issuer, Canaria Transaction Corporation and Serina AL (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of capital stock was exchanged for 0.97682654 shares of the Issuer's common stock, giving effect to a reverse split of the Issuer's common stock of 1-for-35.17.
Footnote F2
The stock options are fully vested.